Factors Associated With Altmetric Attention Scores for Randomized Phase III Cancer Clinical Trials

被引:0
|
作者
Rooney, Michael K. [1 ]
Sharifi, Bahareh [1 ]
Ludmir, Ethan B. [1 ]
Fuller, Clifton D. [1 ]
Warner, Jeremy L. [2 ,3 ,4 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX USA
[2] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA
[3] Lifespan Canc Inst, Providence, RI USA
[4] Brown Univ, 231 Elmgrove Ave,PRB 777, Providence, RI 02906 USA
来源
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Altmetric Attention Scores (Altmetrics) are real-time measures of scientific impact and attention through various public outlets, including news, blogs, and social media. Herein, we aimed to describe and characterize the relationship between Altmetrics, conventional impact metrics, and features of published cancer clinical trials.METHODS We identified two-arm phase III cancer randomized clinical trials with a superiority end point and publication date between 2015 and 2020 from HemOnc and tabulated the following data: Altmetric, study positivity, US Food and Drug Administration (FDA) registration trial status, cancer site/category, treatment context (curative or palliative), trial design, primary end point type, experimental/control arm modality, and journal tier. We further collected conventional bibliometrics including the number of citations and relative citation ratio (RCR) for all published studies. Multiple linear regression modeling identified clinical trial factors predictive of Altmetrics, with alpha = .05 defining statistical significance.RESULTS Altmetrics were found for 681 (98%) of 698 publications, with a median score of 38.5 (IQR, 13-132.8). FDA registration studies (beta [95% CI], 84.7 [48.8 to 120.6]; P < .001), studies reporting on curative (as opposed to palliative) interventions (-29 [-53.7 to -4.4]; P = .02), genitourinary trials (73.2 [28.1 to 118.2]; P = .001), studies published in tier 1 journals (P < .001), and those with an increased number of citations per year (0.81 [0.66 to 0.95]; P < .001) were significantly associated with increased engagement as measured by Altmetrics. Furthermore, there was a strong correlation between all collected bibliometrics and Altmetrics (R2 = 0.63, 0.68, and 0.67; P < .001 for citation count, citations per year, and RCR, respectively).CONCLUSION FDA registration trials describing curative interventions, studies published in traditionally defined high-impact journals, and genitourinary trial publications tend to have the greatest Altmetrics. We observed a strong relationship between Altmetrics and conventional bibliometrics. The significance and consequences of these relationships warrant further investigation.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Performance Status Restriction in Phase III Cancer Clinical Trials
    Jaoude, Joseph Abi
    Kouzy, Ramez
    Mainwaring, Walker
    Lin, Timothy A.
    Miller, Austin B.
    Jethanandani, Amit
    Espinoza, Andres F.
    Pasalic, Dario
    Verma, Vivek
    VanderWalde, Noam A.
    Smith, Benjamin D.
    Smith, Grace L.
    Fuller, C. David
    Das, Prajnan
    Minsky, Bruce D.
    Roedel, Claus
    Fokas, Emmanouil
    Jagsi, Reshma
    Thomas, Charles R., Jr.
    Subbiah, Ishwaria M.
    Taniguchi, Cullen M.
    Ludmir, Ethan B.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (10): : 1322 - 1326
  • [22] Phase III randomized trials of docetaxel in patients with metastatic breast cancer
    Crown, J
    SEMINARS IN ONCOLOGY, 1999, 26 (03) : 33 - 38
  • [23] Sample size estimation in phase III cancer clinical trials
    Curran, D
    Sylvester, RJ
    Boes, GH
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1999, 25 (03): : 244 - 250
  • [24] SIZE OF PHASE-III CANCER CLINICAL-TRIALS
    SIMON, R
    CANCER TREATMENT REPORTS, 1985, 69 (10): : 1087 - 1093
  • [25] ETHICAL ISSUES AROUND PHASE I AND PHASE III CLINICAL TRIALS IN CANCER
    Tattersall, Martin H. N.
    CANCER FORUM, 2016, 40 (02) : 128 - 131
  • [26] Current phase II and phase III clinical trials in the treatment of colorectal cancer
    Mooney, MM
    Schoenfeldt, M
    ONCOLOGY-NEW YORK, 2004, 18 (11): : 1396 - +
  • [27] Factors associated with the successful completion of randomized clinical trials in gynecological oncology
    Swailes, A.
    Gupta, M.
    Chauhan, S. P.
    Kesterson, J.
    Wagner, S.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 127 - 127
  • [28] Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review
    Sperduti, Isabella
    Vici, Patrizia
    Tinari, Nicola
    Gamucci, Teresa
    De Tursi, Michele
    Cortese, Giada
    Grassadonia, Antonino
    Iacobelli, Stefano
    Natoli, Clara
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2013, 32
  • [29] Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review
    Isabella Sperduti
    Patrizia Vici
    Nicola Tinari
    Teresa Gamucci
    Michele De Tursi
    Giada Cortese
    Antonino Grassadonia
    Stefano Iacobelli
    Clara Natoli
    Journal of Experimental & Clinical Cancer Research, 32
  • [30] Clinical estimation of α/β values for prostate cancer from isoeffective phase III randomized trials with moderately hypofractionated radiotherapy
    Datta, Niloy R.
    Stutz, Emanuel
    Rogers, Susanne
    Bodis, Stephan
    ACTA ONCOLOGICA, 2018, 57 (07) : 883 - 894